Clinical Trials Logo

Resistant Cancer clinical trials

View clinical trials related to Resistant Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05718882 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC

Start date: July 1, 2023
Phase: N/A
Study type: Interventional

This is a prospective clinical study aiming to test the safety and efficacy of lenvatinib in combination with Aurora kinase A inhibitor VIC-1911 in participate with lenvatinib-unresponsive or lenvatinib-resistant hepatocellular carcinoma(HCC).

NCT ID: NCT04292119 Recruiting - Lung Cancer Clinical Trials

Lorlatinib Combinations in Lung Cancer

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155